{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Efgartigimod+PH20+SC",
    "query": {
      "intervention": "Efgartigimod PH20 SC"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 29,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Efgartigimod+PH20+SC&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-27T01:02:11.873Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07673627",
      "title": "ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "AChR-Ab Seropositive Generalized Myasthenia Gravis",
        "Myasthenia Gravis (MG)",
        "MG - Myasthenia Gravis",
        "gMG"
      ],
      "interventions": [
        {
          "name": "Empasiprubart IV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo IV",
          "type": "OTHER"
        },
        {
          "name": "Efgartigimod PH20 SC PFS",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "argenx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2026-07-10",
      "completion_date": "2028-04",
      "has_results": false,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-09-27T01:02:11.873Z",
      "location_count": 4,
      "location_summary": "Miami, Florida • Amherst, New York • Chattanooga, Tennessee + 1 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Amherst",
          "state": "New York"
        },
        {
          "city": "Chattanooga",
          "state": "Tennessee"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07673627"
    },
    {
      "nct_id": "NCT05681481",
      "title": "A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bullous Pemphigoid"
      ],
      "interventions": [
        {
          "name": "efgartigimod PH20 SC",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "argenx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2023-03-22",
      "completion_date": "2025-03-20",
      "has_results": true,
      "last_update_posted_date": "2026-02-25",
      "last_synced_at": "2026-09-27T01:02:11.873Z",
      "location_count": 6,
      "location_summary": "Phoenix, Arizona • Fountain Valley, California • Miami, Florida + 3 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05681481"
    },
    {
      "nct_id": "NCT05267600",
      "title": "A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Bullous Pemphigoid"
      ],
      "interventions": [
        {
          "name": "efgartigimod PH20 SC",
          "type": "BIOLOGICAL"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "argenx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 98,
      "start_date": "2022-06-09",
      "completion_date": "2024-09-13",
      "has_results": true,
      "last_update_posted_date": "2025-10-23",
      "last_synced_at": "2026-09-27T01:02:11.873Z",
      "location_count": 21,
      "location_summary": "Phoenix, Arizona • Fountain Valley, California • Redwood City, California + 18 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Castle Rock",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05267600"
    },
    {
      "nct_id": "NCT04812925",
      "title": "A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Immune Thrombocytopenia"
      ],
      "interventions": [
        {
          "name": "efgartigimod PH20 SC",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "argenx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 173,
      "start_date": "2021-11-17",
      "completion_date": "2026-10-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-23",
      "last_synced_at": "2026-09-27T01:02:11.873Z",
      "location_count": 5,
      "location_summary": "Bentonville, Arkansas • Washington D.C., District of Columbia • Fort Wayne, Indiana + 2 more",
      "locations": [
        {
          "city": "Bentonville",
          "state": "Arkansas"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Fort Wayne",
          "state": "Indiana"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04812925"
    },
    {
      "nct_id": "NCT06392386",
      "title": "A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Generalized Myasthenia Gravis"
      ],
      "interventions": [
        {
          "name": "Efgartigimod PH20 SC",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "argenx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 12,
      "start_date": "2024-06-28",
      "completion_date": "2027-09",
      "has_results": false,
      "last_update_posted_date": "2026-09-22",
      "last_synced_at": "2026-09-27T01:02:11.873Z",
      "location_count": 3,
      "location_summary": "Charlotte, North Carolina • Denton, Texas • Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Denton",
          "state": "Texas"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06392386"
    },
    {
      "nct_id": "NCT05374590",
      "title": "Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Generalized Myasthenia Gravis",
        "gMG"
      ],
      "interventions": [
        {
          "name": "Efgartigimod IV or Efgartigimod PH20 SC",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "argenx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "2 Years to 18 Years"
      },
      "enrollment_count": 12,
      "start_date": "2022-08-18",
      "completion_date": "2029-09",
      "has_results": false,
      "last_update_posted_date": "2026-04-23",
      "last_synced_at": "2026-09-27T01:02:11.873Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • Charlotte, North Carolina • Charlottesville, Virginia",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05374590"
    },
    {
      "nct_id": "NCT06307626",
      "title": "A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Thyroid Eye Disease"
      ],
      "interventions": [
        {
          "name": "Efgartigimod PH20 SC",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo PH20 SC",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "OTHER"
      ],
      "sponsor": "argenx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 105,
      "start_date": "2024-03-28",
      "completion_date": "2026-02-12",
      "has_results": false,
      "last_update_posted_date": "2026-03-16",
      "last_synced_at": "2026-09-27T01:02:11.873Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • Mission Hills, California • Rancho Cordova, California + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Mission Hills",
          "state": "California"
        },
        {
          "city": "Rancho Cordova",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Boynton Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06307626"
    },
    {
      "nct_id": "NCT07264426",
      "title": "Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Inflammatory Demyelinating Polyradiculoneuropathy",
        "CIDP",
        "CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)"
      ],
      "interventions": [
        {
          "name": "Efgartigimod PH20 SC",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "argenx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2025-08-11",
      "completion_date": "2029-10",
      "has_results": false,
      "last_update_posted_date": "2026-04-23",
      "last_synced_at": "2026-09-27T01:02:11.873Z",
      "location_count": 1,
      "location_summary": "Wilmington, North Carolina",
      "locations": [
        {
          "city": "Wilmington",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07264426"
    },
    {
      "nct_id": "NCT06299748",
      "title": "A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Myasthenia Gravis",
        "CIDP - Chronic Inflammatory Demyelinating Polyneuropathy"
      ],
      "interventions": [
        {
          "name": "Efgartigimod",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "argenx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 279,
      "start_date": "2023-11-30",
      "completion_date": "2033-12",
      "has_results": false,
      "last_update_posted_date": "2026-02-17",
      "last_synced_at": "2026-09-27T01:02:11.873Z",
      "location_count": 1,
      "location_summary": "Morgantown, West Virginia",
      "locations": [
        {
          "city": "Morgantown",
          "state": "West Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06299748"
    },
    {
      "nct_id": "NCT07583641",
      "title": "A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and Adults",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Autoimmune Encephalitis (AE)"
      ],
      "interventions": [
        {
          "name": "Efgartigimod PH20 (ARGX-113) SC",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo PH20 SC",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "argenx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 170,
      "start_date": "2027-04-01",
      "completion_date": "2030-07-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-22",
      "last_synced_at": "2026-09-27T01:02:11.873Z",
      "location_count": 2,
      "location_summary": "Tucson, Arizona • Sherman, Texas",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Sherman",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07583641"
    }
  ]
}